> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# JPMorgan Reports 5.3% Passive Stake In REGENXBIO, 3,560,915 Shares, In SEC Filing
- URL: https://www.bullished.co/jpmorgan-reports-5-3-passive-stake-in-regenxbio-3-560-915-shares-in-sec-filing-af469bd6/
- Published: 2026-10-13T18:11:38.000Z
- Updated: 2026-11-05T20:59:02.000Z
- Description: The bank's Schedule 13G lists a September 30, 2026 triggering event and sole voting power over 3,324,340 shares.
- Author: Matteo Parrino
- Tags: SEC Filings, RGNX, Industry: Healthcare

JPMorgan Chase holds [5.3% of REGENXBIO's common stock](https://www.sec.gov/Archives/edgar/data/0000019617/000001961726000350/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), or 3,560,915 shares, according to a passive ownership filing (Schedule 13G) dated Tuesday. The filing lists September 30, 2026 as the date of the event that triggered it.

## What the filing says

JPMorgan Chase files as a parent holding company. The stake sits in J.P. Morgan Securities, JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management, the filing says.

It has sole voting power over [3,324,340](https://www.sec.gov/Archives/edgar/data/0000019617/000001961726000350/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of the shares and shared voting power over none. The 5.3% is counted on the Rule 13d-3 basis, which includes shares the holder could acquire within 60 days.

The bank certifies that the shares were acquired and are held in the ordinary course of business. It also certifies they were not bought to change or influence control of [REGENXBIO](https://www.bullished.co/tag/rgnx/).

## What it changes

A passive filing carries no stated plan to seek control, so it is a disclosure of ownership rather than an activist move. In Tuesday trading as of 2:07 p.m. ET, REGENXBIO shares were at $7.19, down 7.46% from the prior close of $7.77, for a market value of $513 million.

The filing does not tie that price move to the stake.

## What to watch

REGENXBIO [will host an investor event](https://www.prnewswire.com/news-releases/regenxbio-to-host-investor-event-highlighting-surabgene-lomparvovec-sura-vec-in-wet-amd-on-october-20-302905229.html?ref=bullished.co) at 1:00 p.m. ET on October 20 on sura-vec, its gene therapy for wet age-related macular degeneration, developed with AbbVie. Topline pivotal data are anticipated in the fourth quarter of 2026.

Separately, a Delaware patent suit against Sarepta, over a University of Pennsylvania gene therapy patent licensed to REGENXBIO, was [dropped](https://www.law360.com/articles/2536303/gene-therapy-patent-suit-against-sarepta-comes-to-close?ref=bullished.co) after the parties agreed to end the case.

The next dated event is the October 20 sura-vec investor event.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — JPMORGAN CHASE & CO. re: REGENXBIO Inc. (RGNX)](https://www.sec.gov/Archives/edgar/data/0000019617/000001961726000350/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Gene Therapy Patent Suit Against Sarepta Comes To Close - Law360](https://www.law360.com/articles/2536303/gene-therapy-patent-suit-against-sarepta-comes-to-close?ref=bullished.co) — law360.com
- [REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20](https://www.prnewswire.com/news-releases/regenxbio-to-host-investor-event-highlighting-surabgene-lomparvovec-sura-vec-in-wet-amd-on-october-20-302905229.html?ref=bullished.co) — prnewswire.com

### More on REGENXBIO

- [REGENXBIO Chairman Kenneth Mills Resigns From Board After Taking CEO Job Elsewhere](https://www.bullished.co/regenxbio-chairman-kenneth-mills-resigns-from-board-after-taking-ceo-job-elsewhere-023eb9df/)

[All REGENXBIO (RGNX) coverage →](https://www.bullished.co/tag/rgnx/)